TITLE

Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism

AUTHOR(S)
Zhao, X.; Imig, J.D.
PUB. DATE
February 2003
SOURCE
Current Drug Metabolism;Feb2003, Vol. 4 Issue 1, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Arachidonic acid can be metabolized by cytochrome P450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosatrienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE). These arachidonic acid metabolites are involved in the regulation of renal epithelial transport and vascular function. 20- HETE and EETs are produced in the renal microvascular smooth muscle cells and endothelial cells, respectively. 20-HETE constricts the preglomerular arterioles by inhibiting K+ channels, and contributes importantly to renal blood flow autoregulatory responsiveness of the afferent arterioles. EETs dilate the preglomerular arterioles by activating the renal smooth muscle cell Ca2+-activated K+ channels and hyperpolarizing smooth muscle cells. These EET actions are consistent with their identification as endotheliumderived hyperpolarizing factors (EDHFs). In the kidney, EETs and 20-HETE are also produced in the proximal tubule and the thick ascending loop of Henle, and these metabolites modulate ion transport in the proximal tubules and the thick ascending limb by inhibiting Na+-K+-ATPase and the Na+-K+-2Cl- cotransporter. CYP450 metabolites also act as second messengers for many paracrine and hormonal agents, including endothelin, nitric oxide, and angiotensin II. The production of kidney CYP450 arachidonic acid metabolites is altered in diabetes, pregnancy, hepatorenal syndrome, and in various models of hypertension, and it is likely that changes in this system contribute to the abnormalities in renal function that are associated with many of these conditions.
ACCESSION #
11156672

 

Related Articles

  • Prediction of Human Drug Metabolizing Enzyme Induction. Mankowski, Dayna C.; Ekins, Sean // Current Drug Metabolism;Oct2003, Vol. 4 Issue 5, p381 

    New chemical entities are routinely screened in vitro and in vivo for their ability to induce cytochrome P450s (CYP), other drug-metabolizing enzymes and possibly transporters in an attempt to more accurately predict clinical parameters such as drug-drug interactions and clearance in humans....

  • Human Cytochromes P450 Associated with the Phase 1 Metabolism of Drugs and other Xenobiotics: A Compilation of Substrates and Inhibitors of the CYP1, CYP2 and CYP3 Families. Lewis, David F.V. // Current Medicinal Chemistry;Oct2003, Vol. 10 Issue 19, p1955 

    This review represents a compilation of typical substrates and inhibitors for human cytochrome P450 (CYP) enzymes that are involved in drug metabolism, specifically those from the CYP1, CYP2 and CYP3 families. Relatively recent literature on substrates and inhibitors has been collected and the...

  • The Effect of Psoralens on Hepatic and Cutaneous Drug Metabolizing Enzymes and Cytochrome P-450. Bickers, David R.; Mukhtar, Hasan; Molica Jr., S. J.; Pathak, Madhu A. // Journal of Investigative Dermatology;Sep82, Vol. 79 Issue 3, p201 

    Psoralens are tricyclic furocoumarins with potent photosensitizing properties in the skin and are now widely used in the treatment of several dermatologic diseases. In this study the effect of 3 different psoralens 8-methoxypsoralen (8-MOP), 4,5',8-trimethylpsoralen (TMP) and isopsoralen on...

  • A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. Kriegl, Jan; Arnhold, Thomas; Beck, Bernd; Fox, Thomas // Journal of Computer-Aided Molecular Design;Mar2005, Vol. 19 Issue 3, p189 

    The cytochrome P450 (CYP) enzyme superfamily plays a major role in the metabolism of commercially available drugs. Inhibition of these enzymes by a drug may result in a plasma level increase of another drug, thus leading to unwanted drug–drug interactions when two or more drugs are...

  • Electronic and Structural Aspects of P450-Mediated Drug Metabolism. Lewis, David F. V.; Ito, Yuko; Lake, Brian G. // Drug Metabolism Letters;Apr2009, Vol. 3 Issue 2, p87 

    From a consideration of first principles for enzymes kinetics, we have employed theoretical methods which enable one to analyse the kinetics of cytochrome P450-mediated reactions which have been based on the known physicochemical principles underlying the majority of chemical or enzymatic...

  • Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development. Nettleton, David O.; Einolf, Heidi J. // Current Topics in Medicinal Chemistry;Feb2011, Vol. 11 Issue 4, p382 

    Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs. CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic...

  • Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450. Niwa, Toshiro; Murayama, Norie; Yamazaki, Hiroshi // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p700 

    Cytochrome P450s (P450 or CYPs) comprise a superfamily of enzymes that catalyze the oxidation of a wide variety of xenobiotic chemicals including drugs and environmental carcinogens. Recent studies have demonstrated that endogenous chemicals are also oxidized by human P450s which mainly...

  • Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Bo Wang; Jing Wang; Shui-Qing Huang; Hai-Hao Su; Shu-Feng Zhou // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p781 

    Human cytochrome P450 2C9 (CYP2C9) accounts for ~20% of total hepatic CYP content and metabolizes ~15% clinically used drugs including S-warfarin, tolbutamide, phenytoin, losartan, diclofenac, and celecoxib. To date, there are at least 33 variants of CYP2C9 (*1B through to *34) being identified....

  • Identification and Induction of Cytochrome P450s Involved in the Metabolism of Flavone-8-Acetic Acid in Mice. Minh Hien Pham; Rhinn, Herv�; Auzeil, Nicolas; Regazzetti, Anne; Harami, Djamel Eddine; Scherman, Daniel; Chabot, Guy G. // Drug Metabolism Letters;Apr2011, Vol. 5 Issue 2, p73 

    The metabolism of flavone-8-acetic acid (FAA) has been hypothesized to be partly responsible for its potent anticancer activity in mice. The purpose of this study was to identify the mouse enzymes involved in FAA Phase I metabolism and evaluate their possible induction in vivo by FAA. Mouse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics